1.Twitter (TWTR) continued its epic fall, after reporting flat revenue and disappointing user growth. Snapchat (SNAP) gets to lure unsuspecting traders while Facebook (FB) reaches new highs.2.Strong pellet pricing and expectations of U.S. protectionism lifted Cliffs Natural Resources’ (CLF) prospects. $CLF, Cleveland-Cliffs Inc. / D 3.Beware of “double top” in shares of Intel Corporation (INTC).4.As predicted Nvidia (NVDA) reported another blowout quarter. The CEO pumped the merits of GPU cloud computing power, even claiming this helps detect cancer. Still, revenue beat consensus by $60M and EPS at $1.13 is $0.30 per share over expectations. Nvidia forecast gross margin of ~ 60%. Great quarter.5.Zynga (ZNGA) the maker of my FAVORITE mobile game, Dawn of Titans, reported another loss on revenue of $190.5M. Daily Mobile user (DAU) growth is up a respectable 9%. On the conference call, only one analyst asked most of the questions. ZNGA is a forgotten stock that may interest value investors.6.Glu Mobile (GLUU) fell after reporting results. Traders pumped the stock higher ahead of results, then locked in profits. Predictably, Home Design attracts both male and female players. Covet Fashion caters to the female crowd:“Home Design is definitely a greater mix of males, but still majority of females. The A grades are roughly the same, the loss and profits are same. That’s a pretty wide-wide range of demographics that engage with both games.” 7.EnteroMedics (ETRM) is the great pump and dump and it is creeping higher. Do not expect this stock recovering back to $30.41. Its study demonstrated a 21% drop in weight loss.8.Tesla (TSLA) is at $269..a new high. Perhaps Ford (F) and GM (GM) are value traps and EV are the growth picks of the future.Ford's GT is still nicer than a Tesla Model S:9.As one of the top value picks here, expect Qualcomm (QCOM) underperforming the chip sector. Related: NXPI Semiconductor buyout. 10.iRobot Corporation (IRBT) plunged 13% on Feb 9. After a solid ER, traders are locking in profits. It’s a “sell on the news.”11.Readers enjoyed my AMD PT $15 analysis (links to InvestorPlace.com). Mark your calendar! Ryzen’s launch is in early-March. $AMD, Advanced Micro Devices, Inc. / D 12.Reader interest in Valeant Pharmaceuticals (VRX) PT $45. VRX reports later this month. Approval for Brodalumab is a catalyst for the stock next quarter. Sales growth at B+L at 7 – 9% should give the share price some support. Management must demonstrate that it solved sales growth challenges at Salix through higher marketing spend and effective doctor education for Xifaxan. The latter’s measure for success is higher Rx (prescriptions) in the quarter.Post your favorite stocks in the comments below. Simply sign in with your Facebook or StockTwits credentials.